Prognosis of Myocarditis Developing After mRNA COVID-19 Vaccination Compared With Viral Myocarditis.
J Am Coll Cardiol
; 80(24): 2255-2265, 2022 12 13.
Artículo
en Inglés
| MEDLINE | ID: covidwho-2131242
ABSTRACT
BACKGROUND:
Association between messenger RNA (mRNA) COVID-19 vaccines and myocarditis has aroused public concern over vaccine safety.OBJECTIVES:
The goal of this study was to compare the prognosis of this condition with viral infection-related myocarditis over 180 days.METHODS:
A territory-wide electronic public health care database in Hong Kong linked with population-based vaccination records was used to conduct a retrospective cohort study. Since the roll-out of BNT162b2 (Pfizer-BioNTech), patients aged ≥12 years hospitalized with myocarditis within 28 days after BNT162b2 vaccination were compared against viral infection-related myocarditis recorded before the pandemic (2000-2019), over a 180-day follow-up period (starting from diagnosis of myocarditis). All-cause mortality, heart failure, dilated cardiomyopathy, heart transplant, and postdischarge health care utilization were examined with Cox proportional hazards models.RESULTS:
A total of 866 patients were included for analysis. Over the follow-up period, 1 death (1.0%) of 104 patients with postvaccination myocarditis and 84 deaths (11.0%) of 762 patients with viral infection-related myocarditis were identified. One case (1.0%) of dilated cardiomyopathy and 2 cases (1.9%) of heart failure were identified in the postvaccination group, compared with 28 (3.7%) and 93 (12.2%) in the viral infection-related myocarditis group, respectively. Adjusted analysis showed that the postvaccination myocarditis group had a 92% lower mortality risk (adjusted HR 0.08; 95% CI 0.01-0.57). No significant differences in other prognostic outcomes were seen.CONCLUSIONS:
This study found a significantly lower rate of mortality among individuals with myocarditis after mRNA vaccination compared with those with viral infection-related myocarditis. Prognosis of this iatrogenic condition may be less severe than naturally acquired viral infection-related myocarditis.Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Virosis
/
Cardiomiopatía Dilatada
/
COVID-19
/
Insuficiencia Cardíaca
/
Miocarditis
Tipo de estudio:
Estudio de cohorte
/
Estudio observacional
/
Estudio pronóstico
Tópicos:
Covid persistente
/
Vacunas
Límite:
Humanos
Idioma:
Inglés
Revista:
J Am Coll Cardiol
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS